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Abstract Recombinant human follicle stimulating hor-
mone (r-hFSH) is effective and safe for controlled ovarian
stimulation. Bemfola (Finox AG, Burgdorf, Switzerland),
a new biosimilar r-hFSH, has proven comparable non-
clinical pharmacological profiles to those of the widely
used Gonal-f (Serono Pharma S.p.A., Bari, Italy). The
objective of this study was to show that Bemfola yields
comparable clinical pharmacokinetic (PK) and safety pro-
files to Gonal-f in healthy female subjects. In this ran-
domized, Phase I trial conducted in healthy female
volunteers (N = 32), a 2-period, balanced 2-treatment
crossover design was used. A single subcutaneous dose of
225 IU Bemfola or Gonal-f was administered in each
treatment period per sequence. Blood was collected for
pharmacokinetic analysis until 10 days after each r-hFSH
treatment. For down-regulation of endogenous FSH sub-
jects were given a depot injection with leuprolide acetate
prior to the study drug in either sequence. Pharmacokinetic
data was available for 23 subjects. No appreciable differ-
ences in key PK parameters were detected between the
r-hFSH products as per non-compartmental PK analysis
[i.e. for Bemfola and Gonal-f respectively AUC0–192
424.90 and 432.75 IU h/L, Cmax 0.98 and 0.95 IU/L, Tmax
24.0 h (range 6.0–24.0) and 24.0 h (range 9.0–24.0), t1/2
43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD
16.47), and Ke 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD
0.002)]. Subgroup analysis for estradiol (E2) response was
similar for Bemfola and Gonal f (AUC(0-–120) p = 0.21
and Cmax p = 0.82). No major safety issues were identified
and no immunogenic reaction to r-hFSH was observed. The
results of this study indicate that a single dose of Bemfola
exhibits pharmacokinetic and safety profiles comparable to
Gonal-f in healthy young women.
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1 Introduction
Bemfola is a biological medicinal product similar to the
licensed Gonal-f (recombinant human follicle-stimulating
hormone r-hFSH, INN Follitropin alfa). Follicle-stimulat-
ing hormone (FSH) is a pituitary glycoprotein hormone
that plays a key role in regulating reproductive function in
both males and females.
FSH is a heterodimeric hormone composed of two
linked subunits. The alpha-subunit (92 amino acids) is
common to other glycoprotein hormones and the beta-
subunit (111 amino acids) is specific.
For clinical use either FSH extracted from the urine of
postmenopausal women (u-hFSH) or recombinant human
FSH (r-hFSH) is used.
For the production of Bemfola, a Chinese hamster
ovary cell line transfected with the genes coding for the
alpha and beta subunits of human FSH is used.
Gonal-f, which has been commercially available since
1995, is an example of a currently marketed r-hFSH
product and is primarily used for treating infertility. In
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particular, Gonal-f is used for ovulation induction in
normogonadotrophic (WHO type II) anovulatory women
and WHO type I anovulatory infertility in association with
a luteinizing hormone (LH) preparation, as well as for
controlled ovarian stimulation in patients undergoing
assisted reproductive technology (ART).
High treatment costs restrict access to high-quality
biological medicines (Schellekens and Moors 2010;
Engelberg et al. 2009); in the case of r-hFSH biosimilar
versions of this recombinant hormone have been developed
in order to provide high-quality alternatives that are more
economically attractive than their present r-hFSH coun-
terparts. Biosimilars meet high standards for comparability
to the originator medicine and are approved for use in the
same indications (Weise et al. 2012).
Bemfola is a r-hFSH biosimilar that has been demon-
strated to have the same physicochemical properties
(Gonal-f SPC 2014; Bemfola SPC 2014) and is mar-
keted in the same therapeutic indications as Gonal-f.
Bemfola has similar non-clinical pharmacological, phar-
macokinetic and toxicological profiles to those of Gonal-f
(Gonal-f SPC 2014; Bemfola SPC 2014).
The current study was performed to examine the phar-
macokinetic bioequivalence of Bemfola to the marketed
product Gonal-f after single subcutaneous administration
in healthy female volunteers. In addition, the safety profiles
of Bemfola and Gonal-f were compared.
2 Materials and methods
Study FIN1001 was a Phase I, randomized, open-label,
crossover trial conducted in healthy female volunteers
between 18 and 38 years of age (N = 32) who were treated
with a single subcutaneous (SC) dose of 225 IU Bemfola
and Gonal-f.
The study was sponsored by Polymun Scientific GmbH
and conducted in Austria at the Medical University of
Vienna, Department of Clinical Pharmacology, between
January and August 2009. All participants received a depot
injection of leuprolide acetate (Enantone-Gyn Depot,
Dual chamber prefilled syringe containing 3.75 mg Leu-
prorelinacetat and 1 mL solvent, Takeda Italia Farmaceu-
tici S.P.A., I-Cerano) for the down-regulation of
endogenous FSH levels. Subjects were randomized to
administration of Bemfola or Gonal-f, followed by a
wash-out period and then crossed over to the alternate
investigational product under study.
The study was approved by the Independent Ethics
Committee of the Medical University of Vienna and was
conducted in accordance with Good Clinical Practice
(GCP), Declaration of Helsinki, the International Confer-
ence on Harmonization guidelines for Good Clinical
Practice CHMP/ICH/135/95, and local regulatory require-
ments/laws. The study is registered with the European
Clinical Trials registry (EudraCT # 2008-006564-11).
Following adequate explanation of the aims, methods,
anticipated benefits, and potential hazards of the study, the
investigator obtained written informed consent from each
subject participating in this study.
2.1 Study population
Healthy female volunteers who fulfilled the following
inclusion criteria were eligible: age between 18 and
38 years; body mass index (BMI) between 17 and 29 kg/
m2; and regular menstrual cycles of 25–34 days before
initiation of oral contraception. Other key inclusion criteria
included (1) use of oral contraceptives for at least 3 months
before study entry; (2) requirement to practice effective
barrier methods for birth control; (3) normal findings in
medical history as well as physical and gynecological
examinations; and (4) presence of both ovaries.
Key exclusion criteria included: (1) polycystic ovary
syndrome (PCOS); (2) history of FSH hypersensitivity [i.e.,
ovarian hyperstimulation syndrome (OHSS)]; (3) history of
malignant disease; (4) presence of hepatic impairment [i.e.,
aspartate aminotransferase (AST]) and/or alanine amino-
transferase (ALT)[2 times the upper limit of normal
(ULN)]; (5) excessive smoking habit (i.e.,[5 cigarettes/
day) or alcohol/drug consumption; (6) pregnancy or lac-
tation period; and (7) other clinically relevant findings per
physical, gynecological or laboratory examination or
symptoms of a clinically relevant illness 3 weeks prior to
the first dose of study drug.
2.2 Study design
A balanced 2-period, 2-treatment crossover design
according to the recommendation for bioequivalence
studies of the European Medicines Agency (‘‘Note for
guidance on the investigation of bioavailability and bio-
equivalence’’; CPMP/EWP/QWP/1401/98) was imple-
mented; hence, subjects were randomly allocated to the
respective treatment sequence. This design minimizes the
inter-subject variability and therefore lowers the required
sample size. A validated software (RANCODE; idv-
Datenanalyse und Versuchsplanung, Gauting, Germany)
was used to generate the randomization schedule using
block randomization with variable block sizes.
2.3 Treatment administration
Eligible subjects received a leuprolide acetate depot
injection between cycle days 15–21 for the down-regula-
tion of their endogenous FSH levels and discontinued oral
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contraceptives on the same day. Ten days after leuprolide
acetate administration (Study Day 1), blood was collected
and serum 17b-estradiol (E2) and FSH analyzed. Volun-
teers were eligible for the next study phase if they had E2
levels B50 pg/mL and FSH levels B4 IU/L, and were
randomized to receive Bemfola or Gonal-f on the next
study day. On Study Day 2, subjects received a single
subcutaneous dose of 225 IU r-hFSH and stayed at the
clinical site for 24 h for PK evaluation. Further blood
collections were performed daily until Study Day 10 (i.e.,
8 days after r-hFSH application). On Study Day 10, sub-
jects received a second depot injection of leuprolide ace-
tate. On Study Day 15, E2 and FSH were controlled, and
the second cycle with application of the other r-hFSH
preparation was initiated on Study Day 16, which followed
an identical schedule. On Study Day 24, the last PK sample
was collected, and physical and gynecological exam, vag-
inal ultrasound, and safety lab examinations were per-
formed. A telephone follow-up was arranged to confirm
that menstrual cycle had resumed.
2.4 Assessments
For the assessment of PK parameters [i.e., maximum
concentration (Cmax), time to maximum concentration
(Tmax), area under the curve between time 0 and 192 h
(AUC0–192), terminal half-life (t1/2), and terminal elimina-
tion rate constant (Ke)] venous blood samples were col-
lected at 0, 0.5, 1, 3, 6, 9, 12, 16, 24, 48, 72, 96, 120, 144,
168, and 192 h after each r-hFSH injection. Serum was
prepared by centrifugation at room temperature (10 min,
3,000 rpm Hettich Rotana TRC centrifuge, r = 194 mm)
and frozen at -70 C until analysis. The serum concen-
trations of FSH and E2 were analyzed using the COBAS
test kit for FSH and E2, respectively (Roche Diagnostics
GmbH, Germany). Assays were performed using modular
analytics E170 analyzer. The method was validated
according ICH Guideline Q2R1 and ISO 5725.
Venous blood samples for immunogenicity testing were
collected at Study Days 1, 15, and 24 and serum was
prepared and frozen as described above. Analysis for anti
FSH antibodies was performed with a validated Surface
Plasmon Resonance method. The limit of quantification
(LoQ) was 57.4 rel RU. All samples tested above the LoQ
were tested in a competition based specificity assay.
For the assessment of safety, all adverse events (AEs)
were reported from the first trial-related activity after
informed consent was given until Study Day 24 (i.e., at
least 192 h after the second r-hFSH injection) per relevant
physical and laboratory examination.
2.5 Endpoints
The primary endpoint was the AUC0–192 of FSH. Sec-
ondary endpoints included other secondary PK parameters
(i.e., Cmax, t1/2, Tmax, Ke) and safety (i.e., AEs, biochemical
monitoring including liver/kidney function, sexual hor-
mones, gynecological examination, ultrasound scans for
solid ovarian cysts, and antibody formation against FSH).
2.6 Statistical methods
The PK parameters were assessed by non-compartmental
analysis. Bioequivalence was investigated by determining
the 90 % confidence limits for the log-transformed ratio
(test product/reference product) for the parameters
AUC(0–192) and Cmax. The null and alternative hypotheses
for determining bioequivalence were tested by using the
difference method implemented in the used validated
statistics program TESTIMATE. This method was
equivalent to fitting an analysis of variance (ANOVA) to
the primary endpoint, where the factors formulation,
period, sequence, and subject nested within sequence
were used to explain the overall variability in the obser-
vations. The sample size was calculated to ensure an
adequate evaluation of the primary endpoint (equal to the
primary objective) and based on a one-sided significance
level of 5 % and a power of 80 %. The intra-subject
variability was estimated to be 15 % based on published
PK data of a bioequivalence study between liquid and
freeze-dried formulation of Gonal-f. Twenty-four ran-
domized subjects were evaluable at the end of the study,
which was within the estimated attrition rate of 15 %.
Values for t1/2 and Ke were calculated using the program
R, Version 2.9.1 with the PK package by Jaki and
Wolfsegger (Estimation of pharmacokinetic parameters
using non-compartmental theory, Windows Binary PK
1.01). The primary efficacy analysis was based on the per
protocol (PP) population, which consisted of all exposed
subjects, who completed the trial and who did not violate
the inclusion/exclusion criteria or other aspects of the
protocol considered to potentially affect the PK results.
The analysis of adverse events, laboratory data, vital
signs, physical examination findings, and other safety
evaluations was performed on the intent-to-treat (ITT),
which included all patients who received at least one dose
of r-hFSH.
Subgroup analysis for E2 increase was performed after
amendment to the study protocol. AUC(0–120) and Cmax of
the serum E2 concentration curves were compared with
paired samples t test.
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3 Results
A total of 32 subjects were enrolled in this trial. Seven
subjects had to be excluded after screening (Fig. 1). A total
of 25 subjects were randomized, one of these subjects was
adversely randomized as the E2 level of B50 pg/mL was
not reached, and consequently, 24 subjects received study
treatment. The mean age of subjects in this study that
received study treatment was 23 years (median 23 years,
range 18–28 years). One subject withdrew from the Be-
mfola-Gonal-f treatment sequence due to an AE (i.e.,
abnormal ultrasound scan). As a result, 23 subjects com-
pleted this study.
3.1 Comparison of AUC(0–192) of Bemfola

to the reference product (Gonal-f)
Mean AUC0–192 after administration of Bemfola
 and
Gonal-f were 424.90 and 432.75 IU h/L, respectively
(Fig. 2; Table 1). The 90 % confidence interval for
AUC0–192 ranged from 0.85 to 1.14 (Table 1) and was
within the bioequivalence acceptance criteria of 0.80–1.25.
No period effect was detectable for AUC0–192 (p = 0.252).
3.2 Comparison of secondary PK parameters
between Bemfola and Gonal-f
No appreciable difference in secondary PK parameters
(i.e., Cmax, t1/2, Tmax, Ke) was observed between Bemfola

and Gonal-f (Table 1). Mean Cmax for Bemfola
 was
observed at 5.69 IU/L and for Gonal-f at 6.01 IU/L, with
a confidence interval of 0.89 to 1.01. In particular, the
median Tmax was identical after FSH application for Be-
mfola and Gonal-f [Bemfola: 24.0 h (range 6.0–24.0);
Gonal-f: 24.0 h (range 9.0–24.0)]. In addition, mean t1/2
values were comparable between Bemfola and Gonal-f
[43.58 h (standard deviation 14.17) vs. 42.58 h (standard
deviation 16.47), respectively]. Similarity was observed for
the elimination rate constant Ke, with 0.0075 1/h calculated
for Bemfola and 0.0077 1/h for Gonal-f. Lastly, no
period effect was seen for Cmax (p = 0.876).
3.3 Comparison of E2 concentration
between Bemfola and Gonal-f
The original study protocol was amended to add an addi-
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E2 serum concentration (AUC) after single application of
Bemfola and Gonal-f.
At this point, the study was already terminated, but spare
serum aliquots reserved for PK analysis were still available
and were used for analysis of E2 serum concentration.
Altogether, 17 out of 24 subjects gave a written consent for
further investigation of their blood samples.
Background for this amendment was the expectation of
detecting an increase in E2 levels even after single application
of r-hFSH to pituitary down-regulated subjects. This increase
could be rated as marker for pharmacodynamic activity of
Bemfola and Gonal-f. The rise in E2 serum concentration
was expected to be low but detectable with a maximum
approximately 24 h after r-hFSH application. Therefore
sample collection times used for determination of FSH serum
concentration were also appropriate for investigating E2.
A low but detectable rise and plateau by 24–48 h in
mean E2 serum concentration was observed after a single
subcutaneous dose of either Bemfola or Gonal-f. The
application of Bemfola induced a stronger increase in
the mean E2 levels than Gonal-f, with a mean AUC0–120
of 3304.3 vs. 2624.3 IU h/L and mean Cmax of 37.72 vs.
30.90 pg/mL, respectively (Fig. 3). The observed differ-
ences were not significant (AUC p = 0.21, Cmax
p = 0.82).
3.4 Adverse event profile
In total, 121 AEs occurred during the course of the study.
94 AEs were mild (78 %), 27 (22 %) were moderate, and
none was severe or serious. 35 AEs (29 %) were drug
unrelated. 86 AEs (71 %) were related to a study drug, with
Table 1 Pharmacokinetic parameters and comparative bioavailability confidence intervals (CIs)
Parameter Treatment
r-hFSH Bemfola (n = 24) Gonal-f (n = 23) 90 % CI (Bemfola vs. Gonal-f)****
Cmax (IU/L) 5.69* 6.01* 94.7 % (89.2 %, 100.6 %)
Tmax (h) 24.0 (6.0–24.0)** 24.0 (9.0–24.0)** –
AUC0–192 (IU h/L) 424.90* 432.75* 98.2 % (84.7 %, 113.9 %)
T1/2 (h) 43.58 (14.17)*** 42.58 (16.47)*** –
Ke (1/h) 0.0075 (0.003)*** 0.0077 (0.002)*** –
Cmax maximum drug concentration, Tmax time to reach maximum drug concentration, AUC0–192h, area under the concentration curve from time 0
to 192 h, t1/2 elimination half-life, Ke elimination rate constant
* Geometric mean
** Median (range)
*** Arithmetic mean (SD)
**** Parametric means
Fig. 2 Mean 192-h corrected profiles of serum concentration of FSH (mIU/mL)—Bemfola vs. Gonal-f
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82 related to leuprolide acetate, 3 AEs were related to
both leuprolide acetate and Bemfola, and 1 to Bemfola
(mild local pain after the application of Bemfola). The
AEs occurring most frequently were headache (63 % of
subjects) and hot flushes (46 % of subjects). One subject
was withdrawn because of an erroneous ultrasound
assessment. All but one subject recovered from their AEs,
with the majority of AEs being mild in nature and
requiring minimal or no therapeutic intervention for res-
olution. The one subject not recovered during the frame of
the study was reported with acne of mild intensity; how-
ever, this was suspected by the investigator to be related
to the leuprolide acetate depot treatment. Results of ECG,
vital signs and physical examinations gave no reason for
clinical concern. No continuous and relevant changes of
the safety laboratory parameters were documented
throughout the study.
3.5 Immunogenicity profile
No specific antibodies to FSH were detected after r-hFSH
administration. In 64 of 72 samples, response signals were
below the limit of Quantification (LoQ). 8 of 72 samples
were above the LoQ (i.e., in the very low range of the
standard curve). Results from a specificity assay demon-
strated that these were background signals unspecific to
FSH. In samples collected at Study Days 15 and 24, the
detected response was similar to the baseline value for all
subjects, and no significant increase was detected (data not
shown).
4 Discussion
The results of Study FIN1001 indicate that 225 IU Bemf-
ola and the reference product Gonal-f administered as a
single dose are bioequivalent based on the systemic
exposure as demonstrated by AUC(0–192). In support of this
key finding, no appreciable differences in Cmax, Tmax, t1/2,
and Ke for r-hFSH were detected as per non-compartmental
PK analysis. The PK and safety findings presented here
therefore support the assumption that Bemfola may be an
acceptable alternative to Gonal-f in the treatment of
infertility.
As a marker for Pharmacodynamic activity of Bemfola
and Gonal-f, a post hoc analysis was conducted, mea-
suring whether an increase in E2 levels could be detected
after a single application of r-hFSH to the pituitary down-
regulated subjects. Both r-hFSH preparations induced a
measurable increase in E2 levels. While there was a ten-
dency to a stronger response to Bemfola, the difference in
AUC and Cmax was not statistically different.
No significant safety issues were reported in this safety
assessment; most AEs were mild in nature and resolved in
response to minimal or no therapeutic intervention. One
subject was withdrawn because of an erroneous ultrasound
assessment. No clinically relevant findings as per ECG,
vital-sign, physical, and laboratory examination were
observed. Immunogenicity to FSH was not evident in this
trial; however, the clinical impact of this observation is not
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Fig. 3 E2 response after single application of Bemfola and Gonal-
f. Subgroup analysis for 17 subjects. Boxplots shot median, 25 and
75 quartiles and minimal and maximal value. a Cmax of E2 (pg/mL]),
b AUC(0–120) of the E2 serum concentration curve (IU h/L) The
difference in AUC and Cmax is not significant (p = 0.21 and 0.82,
respectively)
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The results of this study indicate that a single dose of
Bemfola exhibits pharmacokinetic and safety profiles
comparable to Gonal-f in healthy young women.
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